Cirrhosis

Jump to navigation Jump to search
Cirrhosis
Gross, natural color of liver and stomach view from external surfaces, micronodular cirrhosis and hemorrhagic gastritis (as the surgeon would see these in natural color).
Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology
ICD-10 K70.3, K71.7, K74
ICD-9 571
DiseasesDB 2729
MeSH D008103

Cirrhosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cirrhosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Cirrhosis On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cirrhosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cirrhosis

CDC on Cirrhosis

Cirrhosis in the news

Blogs on Cirrhosis

Directions to Hospitals Treating Cirrhosis

Risk calculators and risk factors for Cirrhosis

WikiDoc Resources for Cirrhosis

Articles

Most recent articles on Cirrhosis

Most cited articles on Cirrhosis

Review articles on Cirrhosis

Articles on Cirrhosis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Cirrhosis

Images of Cirrhosis

Photos of Cirrhosis

Podcasts & MP3s on Cirrhosis

Videos on Cirrhosis

Evidence Based Medicine

Cochrane Collaboration on Cirrhosis

Bandolier on Cirrhosis

TRIP on Cirrhosis

Clinical Trials

Ongoing Trials on Cirrhosis at Clinical Trials.gov

Trial results on Cirrhosis

Clinical Trials on Cirrhosis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cirrhosis

NICE Guidance on Cirrhosis

NHS PRODIGY Guidance

FDA on Cirrhosis

CDC on Cirrhosis

Books

Books on Cirrhosis

News

Cirrhosis in the news

Be alerted to news on Cirrhosis

News trends on Cirrhosis

Commentary

Blogs on Cirrhosis

Definitions

Definitions of Cirrhosis

Patient Resources / Community

Patient resources on Cirrhosis

Discussion groups on Cirrhosis

Patient Handouts on Cirrhosis

Directions to Hospitals Treating Cirrhosis

Risk calculators and risk factors for Cirrhosis

Healthcare Provider Resources

Symptoms of Cirrhosis

Causes & Risk Factors for Cirrhosis

Diagnostic studies for Cirrhosis

Treatment of Cirrhosis

Continuing Medical Education (CME)

CME Programs on Cirrhosis

International

Cirrhosis en Espanol

Cirrhosis en Francais

Business

Cirrhosis in the Marketplace

Patents on Cirrhosis

Experimental / Informatics

List of terms related to Cirrhosis

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Aditya Govindavarjhulla, M.B.B.S. [3]

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differential Diagnosis

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Symptoms | Physical Examination |Laboratory tests | ECG | Endoscopy |CT | MRI |Echocardiography or Ultrasound |Other imaging studies | Alternative diagnostics

Treatment

Medical therapy | Surgical options | Prevention | Financial costs| Future therapies



Diagnosis

Imaging

Computer Tomography

MRI

Other Diagnostic Modalities

If biliary pathology (primary sclerosing cholangitis - PSC) is suspected, ERCP may be performed.

Generally MRCP (MRI of biliary tract and pancreas) is sufficient for diagnosis, but ERCP allows for particular interventions, such as placement of a biliary stent or extraction of gallstones.

Grading

The severity of cirrhosis is commonly classified with the Child-Pugh score. This score uses bilirubin, albumin, INR, presence and severity of ascites and encephalopathy to classify patients in class A, B or C; class A has a favourable prognosis, while class C is at high risk of death. It was devised in 1964 by Child and Turcotte and modified in 1973 by Pugh et al.[1]

More modern scores, used in the allocation of liver transplants but also in other contexts, are the Model for End-Stage Liver Disease (MELD) score and its pediatric counterpart, the Pediatric End-Stage Liver Disease (PELD) score.

Treatment

Traditionally, liver damage from cirrhosis cannot be reversed, but treatment could stop or delay further progression and reduce complications. A healthy diet is encouraged, as cirrhosis may be an energy-consuming process. Close follow-up is often necessary. Antibiotics will be prescribed for infections, and various medications can help with itching. Laxatives, such as lactulose, decrease risk of constipation; their role in preventing encephalopathy is limited.

Treating underlying causes

Alcoholic cirrhosis caused by alcohol abuse is treated by abstaining from alcohol. Treatment for hepatitis-related cirrhosis involves medications used to treat the different types of hepatitis, such as interferon for viral hepatitis and corticosteroids for autoimmune hepatitis. Cirrhosis caused by Wilson's disease, in which copper builds up in organs, is treated with chelation therapy (e.g. penicillamine) to remove the copper.

Preventing further liver damage

Regardless of underlying cause of cirrhosis, alcohol and acetaminophen, as well as other potentially damaging substances, are discouraged. Vaccination of susceptible patients should be considered for Hepatitis A and Hepatitis B.

Chronic Pharmacotherapies

Varices

  • Endoscopic screening in all cirrhotic patients
  • If varices present--treat with propranolol or nadolol

Hepatocellular Cancer

  • Incidence 1-6%/year in HCV-, HBV-, EtOH-related cirrhosis
  • Screening frequency & benefit controversial
  • Serum alpha-fetoprotein (AFP) every 6 months (~60% sensitive, ~90% specific)
  • Ultrasound every 6 months (~75% sensitive, ~90% specific)

Preventing complications

Ascites

Salt restriction is often necessary, as cirrhosis leads to accumulation of salt (sodium retention). Diuretics may be necessary to suppress ascites.

Esophageal variceal bleeding

For portal hypertension, propranolol is a commonly used agent to lower blood pressure over the portal system. In severe complications from portal hypertension, transjugular intrahepatic portosystemic shunting is occasionally indicated to relieve pressure on the portal vein. As this can worsen encephalopathy, it is reserved for those at low risk of encephalopathy, and is generally regarded only as a bridge to liver transplantation or as a palliative measure.

Hepatic encephalopathy

High-protein food increases the nitrogen balance, and would theoretically increase encephalopathy; in the past, this was therefore eliminated as much as possible from the diet. Recent studies show that this assumption was incorrect, and high-protein foods are even encouraged to maintain adequate nutrition.

Hepatorenal syndrome

The hepatorenal syndrome is defined as a urine sodium less than 10 mmol/L and a serum creatinine > 1.5 mg/dl (or 24 hour creatinine clearance less than 40 ml/min) after a trial of volume expansion without diuretics.[2]

Spontaneous bacterial peritonitis

Cirrhotic patients with ascites are at risk of spontaneous bacterial peritonitis.

Transplantation

If complications cannot be controlled or when the liver ceases functioning, liver transplantation is necessary. Survival from liver transplantation has been improving over the 1990s, and the five-year survival rate is now around 80%, depending largely on the severity of disease and other medical problems in the recipient.[3] In the United States, the MELD score (online calculator)[4] is used to prioritize patients for transplantation. Transplantation necessitates the use of immune suppressants (ciclosporin or tacrolimus).

Decompensated cirrhosis

In patients with previously stable cirrhosis, decompensation may occur due to various causes, such as constipation, infection (of any source), increased alcohol intake, medication, bleeding from esophageal varices or dehydration. It may take the form of any of the complications of cirrhosis listed above.

Patients with decompensated cirrhosis generally require admission to hospital, with close monitoring of the fluid balance, mental status, and emphasis on adequate nutrition and medical treatment - often with diuretics, antibiotics, laxatives and/or enemas, thiamine and occasionally steroids, acetylcysteine and pentoxifylline. Administration of saline is generally avoided as it would add to the already high total body sodium content that typically occurs in cirrhosis.

Primary Prevention

  • Education about hepatotoxins:
    • EtOH
    • Acetaminophen
    • Herbals
  • Maintenance of adequate caloric intake: 2000-3000 kcal/d
  • Hepatitis A Virus vaccination, Pneumovax

References

  1. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9. PMID 4541913.
  2. Ginés P, Arroyo V, Quintero E; et al. (1987). "Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study". Gastroenterology. 93 (2): 234–41. PMID 3297907.
  3. E-medicine liver transplant outlook and survival rates
  4. Cosby RL, Yee B, Schrier RW (1989). "New classification with prognostic value in cirrhotic patients". Mineral and electrolyte metabolism. 15 (5): 261–6. PMID 2682175.

External links

  • Cirrhosis of the Liver at the National Digestive Diseases Information Clearinghouse (NDDIC). NIH Publication No. 04-1134, December 2003.
  • [4] at the National Library of Medicine and the National Institutes of Health. Medline Plus: Cirrhosis -- also called: Hepatic fibrosis

Template:Gastroenterology

zh-min-nan:Koaⁿ-ngē-hoà da:Skrumplever de:Leberzirrhose eu:Zirrosi hr:Ciroza jetre is:Skorpulifur it:Cirrosi epatica he:שחמת הכבד la:Cirrosis iecuris ln:Bokɔnɔ bwa libale mk:Цироза nl:Levercirrose no:Skrumplever sq:Cirroza sl:Ciroza jeter fi:Kirroosi sv:Skrumplever


Template:WikiDoc Sources